Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What ever what happened to Ellipsis?? aside from the 8/K that was filed, there is no mention of the "aquisition" in the current 10Q. Thoughts, comments????
Alberta Invests $7M in Genomic Projects
By a GenomeWeb Staff New Reporter
NEW YORK, March 22 (GenomeWeb News) - The Government of Alberta will invest over $4 million in genomics research projects and an additional $3 million to create Genome Alberta to administer and co-fund the projects.
The projects, outlined in a statement today, include canola seed enhancement, wheat resistance to frost, softwood tree genomics, 4D computer imaging of human gene-expression patterns, mouse models for human hereditary disease, and legal and social issues related to genomic technology.
The government expects to secure co-funding for a total of $19 million, according to Alberta's Minister of Innovation and Science, Victor Doerksen.
"The Government of Alberta is committed to developing scientific excellence and continuing to aggressively move forward as a leader in genomics and proteomics," said Doerksen in the statement.
David Bailey was named the new president and CEO of Genome Alberta.
7's, I sent an e-mail to DNAG investor relations on Monday and complained about NITE and OLMP screwing around with the bid and ask. I Wonder if it had any impact?
Jeves it better be good and soon!
I think the 2005 year end results should be out soon which should produce some excitement. The Super EPO dimer will canapult this stock into the stratusphere as well as the Biofrontera IPO
MSN NEWS HOMEPAGE POSTED TODAY:
How African Are You?
What genealogical testing can't tell you.
By John Hawks
Updated Wednesday, March 15, 2006, at 1:43 PM ET
Henry Louis Gates Jr.
Recently on PBS's "African American Lives," host Henry Louis Gates had his DNA tested to learn about his ancestry. Gates' family suspected its paternal ancestry could be traced to a white slave owner. But DNA testing showed that his Y chromosome did not match the man's white descendants. A second, newer test gave Gates another result he didn't expect: His DNA showed that only half of Gates' ancestry was African. The rest were apparently European.
DNA testing for genealogy has become increasingly popular, as a Newsweek cover story in February attests. Especially attention-getting have been efforts to trace genetic relationships along the male lineage. In January the New York Times wrote up attempts to trace Irish genealogy through the male line to Niall of the Nine Hostages, a fifth-century Irish warlord. Other tests have also shown that as many as 14 million men may share the Y chromosome of Genghis Khan. But tests that seek a single, Y-chromosome male lineage are limited: They leave out the vast majority of ancestors. Newer tests can survey all the DNA that can be inherited from either parent, but at a cost of precision: They don't tell which ancestors lived where, and they can't detect traces of ancestry.
The newer "genetic admixture tests" examine DNA from genes inherited from all of a person's grandparents, great-grandparents, and so on. A few of these genes reflect the part of the world where those ancestors lived. Like postcards, they track the movement of people from the lands of their ancestors to their current address. Scientists studying these genetic variations now focus on sites that vary between people by one chemical letter. They're called "single nucleotide polymorphisms," or SNPs. Some of these SNPs are important: They may contribute to traits like skin color or resistance to regional diseases like malaria. Others vary among populations just because of chance.
Continue Article
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
For geneticists, finding the SNPs that mark populations is a challenge. For the most part, the same SNP might be found in Africans, Europeans, and people from every other part of the world. It's now possible to test quickly for hundreds of SNPs by using special microchips that bind to the distinctive DNA sequences. These tests examine hundreds of SNPs at once; if among these a person has many that are common in Africa, it is likely that she has some African ancestors.
Admixture testing works best in groups like African-Americans, whose ancestors in Africa and Europe lived far from each other. Most of the ancestry of today's African-Americans can be traced to West or Central Africa, with a minority from other parts of the continent. (Gates' family is a bit exceptional in terms of origin.)
But for other groups things can get a lot more complicated. Many amateur genealogists are interested in whether they might have a Cherokee ancestor, for example. And for some people, admixture tests can give a relatively accurate answer about Native-American ancestry. But other people, including Greeks and Ashkenazi Jews, may have "Native American affinity," according to the tests, even if they and their ancestors have never been to America. As far as anthropologists know, there were no lost tribes connecting Greeks, Jews, and ancient Americans. So, maybe this "Native American affinity" reflects the scattering of alleles by prehistoric Asian nomads to the ancestors of Greeks and Jews as well as to American Indians. Maybe the SNPs that they share gave these groups a leg up in fighting diseases.
All we know for sure is that such genetic similarities can make ancestry testing very confusing. Suppose a person of mostly German ancestry discovers that his DNA has 6 percent Native-American affinity. Does he have a Native-American ancestor, or a Greek or Jewish ancestor, or all three? There's only one way the 6 percenter can know for sure: He has to know most of his genealogy already.
From a practical point of view, that is the biggest problem with today's genetic genealogy tests. In many cases, they can't tell you what you don't already know. And unlike DNA fingerprinting tests with error rates of one in a billion or less, the chance of misidentifying ancestral groups in these genealogy tests may be 5 percent or higher. With this chance of error, the test won't be wrong about a full Native-American grandparent, but it might be wrong about a great-great grandparent. In addition, SNPs that separate central Africans from northern Europeans aren't nearly as good at separating Ethiopians from Arabs. So, in the test results of some African-Americans, European means Europe, while in others, it may mean East African, or Arab, or Indian. Depending on where his African ancestors came from, Gates' apparently European origins might lie somewhere else entirely.
A deeper problem with admixture testing is its claim to identify the "ancestral components" of different populations. For example, admixture testing considers people from India to be a mixture of "Indo-European" and "East Asian" ancestors. And indeed, Indians have some alleles otherwise common in Europe, and some otherwise common in China. But Indian populations have been on their subcontinent for tens of thousands of years, and they have many alleles that don't come from anywhere else. Anthropologists studying genetic variation have always found complexity rather than simple one-plus-one racial mixtures. SNP-testing companies don't seem to have gotten that news.
SNP-based tests can help you find out where your great-grandfather came from. But his distant ancestors ultimately came from other places. So, most of your genetic ancestry will still be a question mark, no matter how many tests you shell out for.
Related in Slate
--------------------------------------------------------------------------------
In 2005, Arthur Allen explained why, five years after the sequencing of the human genome, these genetic insights have yet to spawn a "superdrug." In 2000, Jon Cohen met a Bantu-speaking member of the Lemba tribe with whom he shares a similar mutation on the Y chromosome. In 1997, Arthur Allen found the geneticists of Gattaca more palatable than the mad scientists of yore.
John Hawks is an anthropologist at the University of Wisconsin-Madison who specializes in human evolution and genetics. He maintains an anthropology weblog.
nuisanceboy, there is no reason for an R/S. the share price will be sufficiently high to avoid any R/S in the future.
If your looking to affect a SP tumble so you can buy back in good luck.
Does anybody here seriously think that $1.2million dollars that Dutchess issued to DNAG is not supported by known factors to payback the debt in a reasonable time frame.
I doubt that any company(investment) would simply be dolling out cash to a company it didn't have an expectation of success or a decent return on their investment.
DNAG has enough advanced pipeline products and current business to meet those expectations in the near term. IMHO.
Also, keep in mind that penny stocks are highly speculative. If you are expecting immediate riches or failure, go buy a lottery ticket, at least then you will have your answer in a day or two.
One of the highest volume days for DNAG in the market today
geob...so your Canadian news was a sham????
OLMP Wacking the ask again..
geob...Prediction? .....
DNAG is "going-to" Cruz .....
GLTA --- GEO
WELL????
eb...sorry it was geob. My mistake.
eb.. Didn't you say there was some news coming from Canada?
500k @ .03 somebody not fooling around
eb.. whats the Canadian News? To be released today?
Huge blocks trading....somethings up
freakin bid wackers!!!!
, March 14, 2006
Transition Therapeutics Acquires Exclusive License to GLP-1 for Type I Diabetes Patent Portfolio
TORONTO, March 14 /CNW/ - Transition Therapeutics Inc. ("Transition")
(TSX: TTH), announced the signing of an exclusive license agreement to a
patent portfolio ("Patent Portfolio") for the use of Glucagon-Like Peptide-1
("GLP-1") analogues in the treatment of Type I diabetes. The Patent Portfolio
includes two issued US patents (US No. 6,989,148 & US No. 6,899,883). The
claims in these issued US patents cover the use of GLP-1 analogues alone or
in combination with insulins for the treatment of Type I diabetes.
The addition of this patent portfolio strengthens the overall intellectual
property protection of Transition's GLP1-I.N.T.™ regenerative product.
The license also provides Transition with exclusivity to key claims
necessary for GLP-1 analogue therapy to extend to Type I diabetes in the
United States.
According to Dr. Joseph Gilbert, Vice-President Research, London Health
Sciences Centre, Director of London Health Sciences Centre Research Inc.
and Chief Administrative Officer at the Lawson Health Research Institute,
"We are pleased to be able to license our GLP-1 intellectual property to a
company such as Transition Therapeutics Inc." Dr. Gilbert further added,
"The existence of emerging Canadian biotechnology companies like Transition
play an important function in the movement of early stage discoveries out of
the laboratory for the benefit of patients."
Transition signed this exclusive license agreement ("Agreement") to the
Patent Portfolio with London Health Sciences Centre Research Inc. ("LHSCRI").
Under the terms of the Agreement, Transition will issue to LHSCRI a number of
Transition common shares having a value of $286,000 at a price equal to the
weighted average trading price of Transition shares from March 15 - March 21,
2006. In addition, LHSCRI is entitled to receive milestone payments and
royalties on amounts actually received by Transition from the net sales of
products covered by issued Patent Portfolio claims or the sublicense of the
Patent Portfolio.
About Transition
Transition is a product-focused biopharmaceutical company, developing novel
therapeutics for disease indications with large markets. Transition's lead
products include regenerative therapies E1-I.N.T.™ and GLP1-I.N.T.™
for the treatment of diabetes, AZD-103 for the treatment of Alzheimer's
disease, MS-I.E.T. for the treatment of multiple sclerosis and HCV-I.E.T. for
the treatment of hepatitis C. Transition is currently enrolling patients for
a Phase II clinical trial for MS-I.E.T. in patients with multiple sclerosis,
and exploratory Phase IIa clinical trials for E1-I.N.T.™ in type I and
type II diabetes patients, and a Phase I/II clinical trial for HCV-I.E.T. in
patients with hepatitis C. Transition's shares are listed on the Toronto
Stock Exchange under the symbol "TTH".
About London Health Sciences Centre Research Inc. and Lawson Health
Research Institute
London Health Sciences Centre Research Inc. (LHSCRI) is a not-for-profit
company that has been established by the London Health Sciences Centre (LHSC)
in London Ontario Canada. The Lawson Health Research Institute (Lawson) is a
joint venture of LHSCRI and Lawson Research Institute, and is the research
arm of LHSC and St. Joseph's Health Care London. Lawson is recognized
worldwide for its research and clinical work spanning the full continuum of
human life. Its unique approach to research guarantees that medical advances
are applied directly to patient care.
Dr. John Dupré, Lawson scientist and inventor of the GLP-1 intellectual
property licensed to Transition, is recognized worldwide as a pioneer in the
clinical investigation of new treatments for patients with Type I diabetes.
Dr. Dupré was part of the group that organized and executed the first-ever
multi-centre international trial of intensive insulin therapy, the first-ever
secondary prevention trial, CANENDIT and the first-ever primary prevention
trial, TRIGR, that recruited newborns at risk of Type 1 diabetes across
Canada, the United States, Europe, and in Australia.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC or otherwise. Press releases may contain forward-looking
statements based on the expectations of our management as of the date of the
release. Actual results may materially differ based on many factors,
including those described in the press releases.
bid wackers suck
It's BUY or BYE!!
I predict .15 by weeks end
bid wackers suck
Jever.. the BIG NEWS we need is that they finally going to have OLMP and NITE traders investigated for illegally manipulating this stock.
Notice how the bid is undercut on a daily basis after a good run? and by the end of the day close to it's high? to start the same cycle over and over?
Until the SEC steps in on this type of activity many micro-cap company investors are going to be bilked out of their investments.
Contrary to Dr. Fud's belief that Management is the root of this Co's poor financing record it dosen't take a genius to see the obvious.
Jeves0000 did ya make any money pattern trading today?! By the way what ever happened to ilwill?
Well at least the ask held firm most of the day! Nice close
the bid wackers are out in full force
Orchid Fires CEO Kelly, Appoints New Head and Provides '05 Guidance
By a GenomeWeb News staff reporter
NEW YORK, March 9 (GenomeWeb News) - Orchid Cellmark fired CEO Paul Kelly yesterday and appointed Thomas Bologna to take his place on April 3, or until the company files its 2005 earnings report, according to documents filed today with the US Securities and Exchange Commission.
Meantime, George Poste, chairman of Orchid's board, will serve as CEO until the company files its earnings for the year ended Dec. 31, 2005, or until April 3, whichever is latest, the documents said.
The company separately provided financial guidance for 2005 in a statement released today.
Bologna, former president and director of Quorex Pharmaceuticals, has been appointed Orchid's CEO for a four-year term, Orchid said. He will receive a commencement bonus of $100,000 within 30 day of his commencement date, and he will be paid an annual base salary of $520,0000, with an annual bonus target of 50 percent of his salary, depending on his performance, the company said.
The company said in a separate statement that it expects revenues for 2005 to be between $61 million and $62 million. The company expects its earnings to reflect a fiscal year, 2005, loss of about $8 million.
Now if the bid whackers would hit the road and sellers would pay attention to the trend we would all be in better shape IMHO
don't ya love it when somebody sells below the current price
rxirish
Knowledge at Wharton [knowledge@wharton.upenn.edu]
Bigdive..don't forget this 10Q is only thru 9/2005 and does not include the 4th qtr. ended 12/2005.
10Q/SB and 8K's are out!
Good Read:
Personalized Medicine and Nanotechnology: Trying to Bring Dreams to Market
While personalized medicine and nanotechnology are still buzzwords rather than significant product generators, both have the potential to produce revolutionary commercial changes, according to scholars and business people who met at Wharton last month to talk about leading-edge industries. Their discussion was part of the Emerging Technologies Update Day sponsored by the Mack Center for Technological Innovation.
Personalized medicine denotes treatments tailored individually to patients. It springs from a growing understanding of genomics and augurs an ability to formulate the precise drug and dosage that every patient needs. Nanotechnology covers anything that can be done at the so-called nanoscale -- between 1 and 100 nanometers. A nanometer is a billionth of a meter; a human hair is about 80,000 nanometers wide. "It's not one technology," says Christine Peterson, vice president for policy and research at the Foresight Nanotech Institute in Palo Alto, Calif. "It's a lot of different technologies. There are nanomaterials, nanodevices and nanosystems."
Personalized medicine is closer than nanotechnology to yielding widespread benefits. Some scientists argue that it arrived, in a limited way, years ago. "Millions of Americans with potential thyroid problems get two tests, and from those tests, we know exactly what medicine they need and what dose to prescribe," says Bob McCormack, vice president for clinical and technical affairs at Veridex, a subsidiary of Johnson & Johnson.
Yet the treatment of many illnesses, and thus many patients, remains a process of trial and error, says Christine Côté, Johnson & Johnson's vice president for emerging technologies and new ventures. "Today, medicine is one size fits all. Diseases and patients are heterogeneous, and therefore treatments need to be individualized. Personalized medicine means the right medicine for the right person at the right time."
People understandably marvel at the pharmaceutical industry's advances. After all, pills and vaccines have knocked out whole classes of illnesses that just a few decades ago might have been fatal. But some modern drugs, even widely prescribed ones, don't work as well as many people believe, Côté says. Beta-blockers, a common treatment for cardiovascular disease, aren't effective for 15 million to 20 million patients, and anti-depressants don't help between 20 million and 50 million individuals for whom they are prescribed.
Some drugs and dosages do serious harm. "Improper medications account for about 100,000 deaths a year," Côté notes. Several high-profile medications, including Vioxx, a Merck painkiller, and Johnson & Johnson's Propulsid, a heartburn aide, have been withdrawn recently because of concerns about side effects linked to heart trouble. Yet these drugs also helped many patients who didn't have serious side effects. In a world of personalized medicine, doctors could distinguish between patients who would benefit from Vioxx -- or any drug -- and those who might be harmed.
Genomics offers the key to making these distinctions. A greater understanding of the human genome is giving physicians the ability to identify people with predispositions to particular diseases and to design drugs that target particular genes, Côté points out. Consider Herceptin, a breast cancer drug made by Genentech. It's given to patients with an unusual gene called HER2. The gene can lead to the overproduction of a protein that, in turn, can contribute to a fast-growing form of cancer.
The same sort of genomic technology underpins Veridex, according to McCormack. The company, which Johnson & Johnson formed in 2004, makes cancer tests, including one that predicts the probability of early breast cancer recurrence.
Today, many breast cancer patients have their tumors removed and then receive chemotherapy. But chemotherapy can have serious side effects, and not all women need it, McCormack points out. By identifying women with a high likelihood of recurrence, Veridex's test could allow oncologists to spare low-likelihood patients from unneeded chemotherapy. "The goods news here is that we have a great opportunity to decrease the amount of unnecessary treatment and cost, save anywhere from $10,000 to $75,000 per patient and focus our efforts on the at-risk patients," McCormack notes. "The bad news is that personalized medicine has a price. Are you willing to withhold any therapy from your wife or mother for cost savings?"
These sorts of questions will become more urgent over the next few years because Americans, on average, are getting older and sicker. "Baby Boomers are 30% of the U.S. population, and they are aging," Côté says. "Seniors consume three times more drugs than their working counterparts. At the same time, two-thirds of adults are overweight and 15% of kids are. Obesity is related to a host of diseases, including diabetes, heart disease and stroke." When you add rising healthcare costs to the mix, consumers, insurers and employers won't be able to avoid dilemmas like the one posed by Veridex's test.
Stain-, Static- and Stink-Resistant
Nanotechnology has applications in the treatment of cancer, too. Scientists are talking about using silica spheres coated with gold to attack tumors, Peterson says. Infrared light would heat the gold, and the heat would kill the cancer. Likewise, nanofilters could be used to purify blood.
Few industries will remain untouched by nanotechnology in some way, she adds. Already, companies are rolling out consumer goods that harness it. Beach lifeguards no longer look like they are smeared with white war paint because their facial sun block has been replaced by a "nanocrystalline" version. The sunscreen formerly contained "particles that reflected light. Now they use the same sort of stuff, but the particles are smaller and don't reflect light."
Perhaps the most ballyhooed nanotech products -- besides the iPod Nano, which really isn't one -- are fabrics produced by California-based Nano-Tex. They resist stains and static and breathe better than many conventional ones. To make its stain-resistant fibers, the company combines hydrophobic whiskers with normal cotton molecules. The whiskers prevent stain absorption but don't affect the feel of the fabric. Companies like Gap and Eddie Bauer are using the technology in their clothing. Another recent Nano-Tex innovation is odor-resistant socks, Peterson says. They contain particles of charcoal and silver that absorb odors.
Even though he works for a nanotech pioneer, Bill Perry, vice president of marketing, sales and business development at Nanomix, a sensor maker, counts himself among the nanotechnology skeptics -- at least when it comes to some of the sector's more self-promotional claims. "What you look for in nanotechnology are the same things that you look for in any business," he says. Seeking out "nanotechnology for its own sake is silly. Nano pants are great, but they had better help you sell more pants."
According to Perry, his company has found such a practical application. A spinout from the University of California at Berkeley, Nanomix makes sensors out of carbon nanotubes. These tiny cylinders of graphite, with walls the width of a single carbon atom, have a diameter of only 1 or 2 nanometers, about the same size as a strand of DNA.
Nanomix's founders, a chemist and a physicist at Berkeley, originally planned to use the tubes for molecular storage. They shifted their focus to sensors and have devised one for hydrogen and another for carbon dioxide. The hydrogen detector sniffs out explosive gas, while the one for carbon dioxide helps emergency medical technicians (EMTs) monitor patients' breathing. Nanomix also has begun work on a handheld device that would enable EMTs to determine whether a person is infected with sepsis.
Unlike some conventional sensors, Nanomix's devices consume little power. "Our hydrogen detector can operate for a year on a watch battery," Perry says. As you would expect, its sensors are tiny. Twenty of them can fit on a 2x2 millimeter chip and thus 2,220 chips and multiple sensors can squeeze onto a 6-inch wafer.
So what's the future for this industry, which aims to get big while staying small? At the technological level, more companies will follow Nanomix's example and build from the molecular level upwards, Peterson predicts. "Now the typical approach is top-down -- taking big stuff and making it smaller."
Along the way, proponents will undoubtedly have to fight public relations battles because some environmental and public-health advocates have raised concerns about the dangers of these effectively invisible engineering projects. One study, at Southern Methodist University, found that fish swimming in water containing nanoparticles called "buckyballs" (soccer-ball shaped synthetic carbon molecules) ended up with brain damage.
DuPont is trying to head off these sorts of challenges by teaming up with Environmental Defense, a green group, to formulate a framework of policies and best practices for nanotech research and commercialization. "The intent of this framework is to define a ... process that can be used to identify, manage and reduce potential health, safety and environmental risks of nanoscale materials across all lifecycle stages," the partners said in an October news release. DuPont intends to test the framework with its inventions.
These guidelines may come into play sooner than many people expect, even though, for now, the United States is a bit of a nanotech laggard, Peterson says. "This isn't science fiction. It's the future of materials science and even healthcare. But the U.S. is only funding nanotechnology at about $1 billion a year. Startups are the most important players here."
At the same time, she, like Perry, cautions that nanotechnology "is often just a marketing phrase, so don't let it affect you positively or negatively. It's like a window; just look right through it. When it comes to starting companies, it's no different than anything else." Profits, not just promise, are what will matter
are we there yet....
seems like NITE and OLMP are at it again. Running up the price then systematically taking out the ask with a low bid
Jever..we need to discover some revenues.
could be...
Good Night..John Boy
Cool Wall Street News Alert
Hot Stocks to Watch! February 27, 2006 Related Stocks
DNAG
ERUG
INTC
WYE
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.
WESTON, FL -- (MARKET WIRE) -- 02/27/06 --
Wall Street News Alert's "stocks to watch" this morning are: ER Urgent Care Centers (ERUG - news) , Intel (INTC - news) , DNAPrint Genomics Incorporated (DNAG - news) , and Wyeth (WYE - news) .
Once again, ER Urgent Care Centers (ERUG - news) will have the attention of investors as the markets begin trading this Monday morning. Friday after the stock markets closed, the company issued a press release announcing the opening of another new clinic; this time in Tampa Florida!
Investors should love the progress and the rate at which the company is expanding with new openings! According to the press release, this clinic will have a major impact on the company's bottom line. "With major insurance companies diverting patients from emergency rooms to our clinic we have expectations of exceeding the original number of 30 patients a day," said Jerry Miller Company Founder and Director at a recent reception at the new clinic. With our recent success in Kansas City we are very proud to come back and open Tampa within such short period of time. As always ER Urgent Care continues to lead the way in the Urgent care industry.
It was just two days prior to this announcement that the company announced the opening of its sixth clinic (this one in Kansas City).
Watch this one closely!
Prior to Friday's press release, the stock closed at around Twelve cents a share.
To view a detailed, in-depth profile of ER Urgent Care Centers, visit http://www.thenewssvc.com/ERUG022606.html
To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit www.WallStreetNewsAlert.com, where you may also sign up to receive free email alerts in advance of our press releases being issued.
In case you are not familiar with the company: ERUC Management Company Inc. operates ER Urgent Care Centers in the South Florida area. The "true, bona-fide," "Urgent Care Center" is a one-stop-shop where patients can receive premier health care, after-hours, at a fraction of the cost of emergency room visits. With the "Urgent Care Center" model emergency rooms will no longer lose money on ER patients with minor injuries and illnesses and the HMOs will no longer have to pay exorbitant claims for non-admitted patients. ER Urgent Care Centers create a win-win situation for everyone, filling the financial and service gap between primary care physicians (PCPs) and hospital emergency rooms.
Stocks showing interesting activity Friday at the close of the regular trading day were: Intel (INTC - news) up 0.3% on 73.1 million shares traded, DNAPrint Genomics, Inc. (DNAG - news) down 9.4% on 11.8 million shares traded, and Wyeth (WYE - news) up 0.7% on 5.6 million shares traded.
Commentary:
"Crude-oil futures jumped over $2 a barrel driven largely by jitters over an explosion in Saudi Arabia Friday, marking a gain of almost 3% for the week. Crude for April delivery climbed as high as $63.25 a barrel on the New York Mercantile Exchange," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: http://www.WallStreetNewsAlert.com